COCH p.P51S变异携带者基因型-表型相关性研究:111例携带者听功能横断面分析
本研究对111例比利时和荷兰的COCH p.P51S变异携带者进行听力学横断面调查,以ISO 7029标准百分位值为参照,通过非线性回归模型确定听力恶化里程碑年龄。结果显示女性携带者听力障碍平均约38岁开始,男性约46岁开始;多数患者在48-50岁可能需要助听器,56-59岁可能需要人工耳蜗。
要点
- p.P51S携带者听力恶化女性平均约38岁开始,男性约46岁开始。
- 多数患者平均48-50岁PTA≥40 dB HL需助听器,56-59岁PTA≥70 dB HL需人工耳蜗。
- 个体间及双耳间不对称性和变异性在所有年龄均较高。
核心结论
- p.P51S携带者感音神经性听力恶化始于第三十年左右,甚至可能更早。
- DFNA9在男女携带者中表型表达相似,但男性携带者早期阶段更难识别。
研究设计与样本
- 横断面研究,纳入111例比利时和荷兰的p.P51S变异携带者进行听力学调查。
- 听力阈值与ISO 7029标准p50th、p95th、p97.5th百分位值比较。
- 采用非线性回归模型分别对男女携带者推导里程碑年龄。
主要发现
- 女性携带者听力障碍平均约38岁开始(范围28-43岁),男性平均约46岁开始(范围42-49岁)。
- 听力恶化开始年龄因频率而异,男女恶化序列存在差异,主要因男性年龄参照限值更严格。
- 预测模型(ARTA)未显示男女表型表达差异。
- 多数DFNA9患者平均48-50岁可能需要传统助听器(PTA≥40 dB HL)。
- 平均56-59岁可能需要人工耳蜗(PTA≥70 dB HL)。
关键数值与推荐
- 助听器 eligibility 基于PTA≥40 dB HL,人工耳蜗基于PTA≥70 dB HL。
- 采用三种PTA:PTA0.5-4(0.5、1、2、4 kHz)、PTA4-8(4和8 kHz)、PTA6-8(6和8 kHz)。
临床怎么用
- 对p.P51S携带者应关注第三十年甚至更早的听力变化,男性携带者早期识别更困难。
- 可根据年龄预测里程碑事件(助听器、人工耳蜗)以指导临床随访和干预时机。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: DFNA9 is characterized by adult-onset progressive sensorineural hearing loss (SNHL) and vestibular impairment. More than 15 years ago, genotype-phenotype correlation studies estimated the initial age of hearing deterioration in the fourth to fifth decade (ranging from 32 to 43 years). However, these analyses were based on relatively limited numbers of mainly symptomatic carriers using markedly different methodologies. The starting point for the hearing deterioration is more correctly determined with larger numbers of carriers and with a more clearly defined starting point of the hearing deterioration. AIM: The aim of this study was to determine milestone ages (start and maximal hearing deterioration, potential eligibility for hearing aids and cochlear implants based on pure-tone average [PTA]) in a large series of p.Pro51Ser COCH variant carriers. The degree of individual interaural asymmetry and the degree of variability (interquartile range) with which the hearing deterioration progresses across ages were also studied, and age-related typical audiograms (ARTA) were constructed. MATERIAL AND METHODS: One hundred eleven Belgian and Dutch p.P51S variant carriers were identified and recruited for audiological investigation. Their hearing thresholds were compared with p50th, p95th, and p97.5th percentile values of presbyacusis (ISO 7029 standards). The onset and degree of hearing deterioration were defined and assessed for each frequency and with three PTAs (PTA0.5-4 [0.5, 1, 2, and 4 kHz]; PTA4-8 [4 and 8 kHz]; and PTA6-8 [6 and 8 kHz]). The milestones ages were derived from nonlinear regression model of hearing thresholds against age, for male and female carriers separately, because of different age-referenced limits. Interaural right-left asymmetry was assessed, and variability of hearing thresholds were calculated using interquartile range. ARTAs were built with both observed data and a prediction model. RESULTS: Hearing dysfunction in p.P51S carriers begins at about 38 years of age (ranging from 28 to 43 years) on average in female and 46 years (ranging from 42 to 49 years) in male carriers (third decade: female, fifth decade: male carriers), depending on the hearing frequency and with differences in deterioration sequence between both genders. These differences, however, were mainly due to more stringent age-referenced limits for men. In contrast, predictions (ARTA) did not show any difference of phenotypic expression between genders. At about 48 to 50 years of age on average, the majority of DFNA9 patients may need conventional hearing aids (PTA ≥ 40 dB HL), whereas this is about 56 to 59 years for cochlear implants (PTA ≥ 70 dB HL). There is a high degree of individual interaural asymmetry and interindividual variability throughout all ages. CONCLUSION: This study demonstrates that the onset of sensorineural hearing deterioration starts in the third decade and probably even earlier. Regardless of differences in estimates, DFNA9 expresses similarly in male and female carriers, but male carriers are much more difficult to identify in early stages of the disease. Comprehensive assessment of the natural course of DFNA9 is of particular interest to predict the age of onset or critical period of most significant function deterioration in individual carriers of the pathogenic variant. This will help to design studies in the search for disease-modifying therapies.
引用
- JanssensdeVarebeke SPF, Moyaert J, Fransen E, et al. Genotype-phenotype Correlation Study in a Large Series of Patients Carrying the p.Pro51Ser (p.P51S) Variant in COCH (DFNA9): Part I-A Cross-sectional Study of Hearing Function in 111 Carriers. Ear Hear. 2021. PMID: 34369416. doi:10.1097/AUD.0000000000001099
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。